Viking Therapeutics, Inc.

As of June 30, 2026, Viking Therapeutics, Inc. carries a market capitalization of 3.98B, placing it among publicly traded companies globally. Its enterprise value stands at 3.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Viking Therapeutics, Inc.'s next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Viking Therapeutics, Inc. has 116.65M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Viking Therapeutics, Inc. maintains a current ratio of 4.72, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Viking Therapeutics, Inc. posted a negative return on equity (ROE) of -88.85, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -79.24, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 48.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Viking Therapeutics, Inc.'s stock has declined approximately 14.77% over the past 52 weeks. The 50-day moving average sits at 27.58, while the 200-day moving average is 28.21.

Over the twelve months ended June 30, 2026, Viking Therapeutics, Inc. generated - - in revenue and converted that into -468.11M in net income, yielding earnings per share of -4.09. EBITDA reached -489.79M, while operating income came in at -490.19M.

As of June 30, 2026, Viking Therapeutics, Inc. holds 439.11M in cash and equivalents against 3.58M in total debt, resulting in a net debt position of -110.07M. Total book value stands at 357.40M, with working capital of 357.04M providing operational flexibility.

Viking Therapeutics, Inc. produced -366.26M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.36: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.44, meaning Viking Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Viking Therapeutics, Inc. has an Altman Z-Score of 18.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.